Scarica l'app Stockscreener
1.68
4.00%
-0.07
Precedente Chiudi:
$1.75
Aprire:
$1.73
Volume 24 ore:
814.06K
Relative Volume:
0.96
Capitalizzazione di mercato:
$220.20M
Reddito:
$34.16M
Utile/perdita netta:
$-50.62M
Rapporto P/E:
-3.3071
EPS:
-0.508
Flusso di cassa netto:
$703.00K
1 W Prestazione:
-6.67%
1M Prestazione:
-19.62%
6M Prestazione:
-62.67%
1 anno Prestazione:
-64.03%
Intervallo 1D:
$1.63
$1.74
Intervallo di 1 settimana:
$1.63
$1.871
Portata 52W:
$1.63
$4.96
Omniab Inc Stock (OABI) Company Profile
Nome
Omniab Inc
Settore
Industria
Telefono
510-250-7800
Indirizzo
5980 HORTON STREET, EMERYVILLE
Confronta OABI con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
OABI
Omniab Inc
|
1.68 | 220.20M | 34.16M | -50.62M | 703.00K | -0.508 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.58 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.92B | 3.81B | -644.79M | -669.77M | -6.24 |
Omniab Inc Stock (OABI) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-11-29 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-04-21 | Iniziato | The Benchmark Company | Buy |
| 2023-04-13 | Iniziato | Craig Hallum | Buy |
| 2023-02-22 | Iniziato | Cowen | Outperform |
| 2023-02-13 | Iniziato | H.C. Wainwright | Buy |
| 2022-12-20 | Iniziato | Truist | Buy |
| 2022-12-16 | Iniziato | Credit Suisse | Outperform |
| 2022-11-29 | Iniziato | SVB Leerink | Outperform |
| 2022-11-28 | Iniziato | Stifel | Buy |
Mostra tutto
Omniab Inc Borsa (OABI) Ultime notizie
OmniAb, Veraxa Biotech Partner on Solid Tumor Drug Discovery Program - marketscreener.com
VERAXA Biotech Enters Co-discovery Alliance with OmniAb for a Novel Bispecific Antibody Drug Conjugate Program - The Manila Times
VERAXA Biotech AG and OmniAb, Inc. Announce Co-Discovery Alliance for Novel Bispecific Antibody Drug Conjugate Program Targeting Solid Tumors - Nasdaq
VERAXA Biotech Enters Co-discovery Alliance with OmniAb for a Novel Bispecific Antibody Drug Conjugate Program - GlobeNewswire Inc.
VERAXA Biotech Enters Co-Discovery Alliance with OmniAb - Contract Pharma
OmniAb Inc [OABI] Records 200-Day SMA of $3.6405 - knoxdaily.com
A stock that deserves closer examination: OmniAb Inc (OABI) - uspostnews.com
OmniAb Inc (OABI) Stock: Navigating Drops and Gains - investchronicle.com
OmniAb to Participate in Five Upcoming Investor Conferences - Business Wire
Legal & General Group Plc Decreases Stock Holdings in OmniAb, Inc. (NASDAQ:OABI) - Defense World
OmniAb Inc (OABI) can make a big difference with a little luck - Sete News
Ratio Examination: OmniAb Inc (OABI)’s Price-to-Cash and Price-to-Free Cash Flow - DWinneX
RBC Capital Mkts initates OmniAb Inc (OABI) stock to an Outperform - knoxdaily.com
Ratios Reveal: Breaking Down OmniAb Inc (OABI)’s Financial Health - DWinneX
OmniAb Inc (OABI) deserves closer scrutiny - uspostnews.com
Companies Like OmniAb (NASDAQ:OABI) Are In A Position To Invest In Growth - Yahoo Finance
OmniAb, Inc. (NASDAQ:OABI) Shares Purchased by Geode Capital Management LLC - Defense World
OmniAb expands board with two new directors By Investing.com - Investing.com South Africa
OmniAb Appoints New Directors to Board - TipRanks
OmniAb adds two new directors to its board - Investing.com Australia
OmniAb adds two new directors to its board By Investing.com - Investing.com India
OmniAb expands board with two new directors - Investing.com Australia
OmniAb Announces Two New Appointments To Its Board Of Directors - marketscreener.com
OmniAb, Inc. Announces Board Changes - marketscreener.com
OmniAb Announces Two New Appointments to its Board of Directors - Business Wire
OmniAb, Inc. (NASDAQ:OABI) Shares Purchased by JPMorgan Chase & Co. - Defense World
OmniAb, Inc. (NASDAQ:OABI) Shares Slammed 29% But Getting In Cheap Might Be Difficult Regardless - simplywall.st
Leerink Partnrs Estimates OmniAb’s Q1 Earnings (NASDAQ:OABI) - Defense World
OmniAb, Inc. (NASDAQ:OABI) Shares Sold by Vanguard Group Inc. - Defense World
OABI: Riding the Market Waves of Growth and Decline in 2023 - investchronicle.com
OmniAb to Report First Quarter 2025 Financial Results on May 8 - Business Wire
OmniAb, Inc. (NASDAQ:OABI) Shares Acquired by American Century Companies Inc. - Defense World
KLP Kapitalforvaltning AS Makes New $49,000 Investment in OmniAb, Inc. (NASDAQ:OABI) - Defense World
OmniAb chief legal officer Charles Berkman sells $14,412 in stock By Investing.com - Investing.com South Africa
OmniAb CEO Matthew Foehr sells $38,764 in company stock By Investing.com - Investing.com India
OmniAb chief legal officer Charles Berkman sells $14,412 in stock - Investing.com Australia
Omniab CFO Kurt Gustafson sells $14,412 in stock - Investing.com
OmniAb CEO Matthew Foehr sells $38,764 in company stock - Investing.com
RBC Capital Sticks to Their Buy Rating for OmniAb (OABI) - The Globe and Mail
OmniAb CFO Kurt Gustafson sells $28,352 in common stock By Investing.com - Investing.com India
OmniAb CFO Kurt Gustafson sells $28,352 in common stock - Investing.com
OmniAb, Inc. (NASDAQ:OABI) Shares Sold by Swiss National Bank - Defense World
Analyst Forecasts Just Became More Bearish On OmniAb, Inc. (NASDAQ:OABI) - Yahoo
Royal Bank of Canada Lowers OmniAb (NASDAQ:OABI) Price Target to $4.00 - Defense World
Charles Schwab Investment Management Inc. Has $2.90 Million Holdings in OmniAb, Inc. (NASDAQ:OABI) - Defense World
March 2025's Promising Penny Stock Opportunities - Yahoo Finance
RBC Cuts Price Target on OmniAb to $4 From $7, Keeps Outperform Rating - MarketScreener
Omniab Inc Azioni (OABI) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.39%
3.66%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):